Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner

Delivery to the Nervous System

Tech Session III: Delivery to the Nervous System I

Novel Biodegradable NanoArtemisinin to Treat Leukemia in Blood and Brain

Wednesday, July 16, 2025
11:38 AM – 11:49 AM EDT
Introduction:

Acute myeloid leukemia (AML) is the most common acute leukemia with an average five-year survival rate of 30%, and much lower (11%) for central nervous system AML subtype. Current treatments for AML have limited efficacy and significant toxicity. Artemisinins-derived ART631 is a potent antileukemic agent, yet its clinical use is hampered by its poor water solubility and short half-life1,2. The objective of this project aimed to develop an ART631-loaded biodegradable nanogel system3 with improved water solubility and a sustained release of ART631 to treat leukemia in both the blood and brain.

Learning Objectives:

At the completion of this activity, participants will know
  • Upon completion, participants will be able to describe the benefits of using nanogel to load ART631.
  • Upon completion, participants will be able to explain the method of characterising NanoART631.
  • Upon completion, participants will be able to understand the evaluation of the efficacy and safety.